Autologous cultured chondrocytes

Identification

Name
Autologous cultured chondrocytes
Accession Number
DB10997
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Cell transplant therapies
Autologous cell transplant
Description

Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma. It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods. The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.

Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarticelImplant1.2e+007 1/1Intra-articularVericel Corporation1905-06-19Not applicableUs
CarticelImplant1.2e+007 1/1Intra-articularGenzyme Corporation1997-08-22Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
MaciAutologous cultured chondrocytes (15000000 1/1) + Pork Collagen (15 cm2/1)ImplantIntra-articularVericel Corporation2017-01-11Not applicableUs
Categories
UNII
D5P3K3V822
CAS number
Not Available

Pharmacology

Indication

Cellular repair strategy for patients with symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea) caused by trauma or patients who were previously unresponsive to available surgical procedures.

Associated Therapies
Pharmacodynamics

Autologous cultured chrondrocytes reduce pain and considerably improve function in patients with defected cartilage at femoral joints by producing hyaline-like cartilage repair tissue.

Mechanism of action

Chrondrocytes are collected from the patient's femoral articular cartilage and isolated cells are expanded through cell culture in vitro. Multiplied chrondrocytes are implanted into articular cartilage defects beneath an autologous periosteal flap. Cells produce hyaline-like cartilage that mainly consists of type II collagen. Type II collagen maintain the macromolecular framework in the extracellular matrix that gives integrity to surrounding hyaline cartilage. The therapy repairs damaged cartilage and restores functional and mechanical ability to withstand compressional, tensile, and shear forces.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Unwanted effects from therapy include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion and graft delamination in less than 5% of total patients who underwent treatment.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Melrose J: The knee joint loose body as a source of viable autologous human chondrocytes. Eur J Histochem. 2016 Jun 10;60(2):2645. doi: 10.4081/ejh.2016.2645. [PubMed:27349321]
  2. Nazempour A, Van Wie BJ: Chondrocytes, Mesenchymal Stem Cells, and Their Combination in Articular Cartilage Regenerative Medicine. Ann Biomed Eng. 2016 May;44(5):1325-54. doi: 10.1007/s10439-016-1575-9. Epub 2016 Mar 17. [PubMed:26987846]
  3. Akkiraju H, Nohe A: Role of Chondrocytes in Cartilage Formation, Progression of Osteoarthritis and Cartilage Regeneration. J Dev Biol. 2015 Dec;3(4):177-192. Epub 2015 Dec 18. [PubMed:27347486]
  4. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994 Oct 6;331(14):889-95. [PubMed:8078550]
  5. Zhang W, Ouyang H, Dass CR, Xu J: Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016 Mar 1;4:15040. doi: 10.1038/boneres.2015.40. eCollection 2016. [PubMed:26962464]
  6. Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grontvedt T, Solheim E, Strand T, Roberts S, Isaksen V, Johansen O: Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am. 2004 Mar;86-A(3):455-64. [PubMed:14996869]
External Links
PubChem Substance
347911074
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Autologous_chondrocyte_implantation
FDA label
Download (142 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentArticular Cartilage Defects / Repair of Articular Cartilage Defects1
3RecruitingTreatmentArticular Cartilage Defects / Articular Cartilage Disorder of Knee / Chondral Defect / Osteochondritis Dissecans1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
ImplantIntra-articular1.2e+007 1/1
ImplantIntra-articular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:05 / Updated on November 02, 2018 07:06